使用 tiagabine 和 zuranolone 的神经类固醇替代疗法恢复小脑神经发育,并减少早产后的过敏行为
Carlton L Pavy1,2, Julia C Shaw1,2, Hannah K Palliser1,2
1School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia.
Journal of developmental origins of health and disease
|January 8, 2025
概括
用 tiagabine 和 zuranolone 进行的神经类固醇替代疗法在保护早产婴儿小脑免受神经发育攻击方面显示出有前途. 这些治疗方法为缓解长期损伤提供了潜在的好处,观察到性别特异性的影响.
科学领域:
- 神经科学是一个神经科学.
- 发展生物学 发展生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过早分娩会导致缺氧-缺血和兴奋毒性侮辱,损害新生儿神经发育.
- 小脑在孕期晚期容易受到这些侮辱,这是一个关键的发育时期.
- 抑制性神经类固醇的损失加剧了与早产相关的神经发育缺陷.
研究的目的:
- 在早产模型中研究使用 tiagabine 和 zuranolone 的神经类固醇替代疗法的神经保护潜力.
- 评估这些疗法对小脑神经发育标志物和行为的影响.
- 探索治疗有效性的潜在性别特异性差异.
主要方法:
- 海豚模型的早产 (妊娠年龄64岁) 和产期 (妊娠年龄70岁).
- 早产的幼接受了提亚丁,祖拉诺或载体治疗,直到相当于期满的年龄.
- 在产后第8天 (PND8) 和PND41进行行为测试;在PND42进行小脑组织分析.
- 通过免疫组织化学评估神经发育标志物 (MBP,OLIG2,NeuN).
- 使用RT-PCR对GABAergic和glutamatergic通路表达的量化.
主要成果:
- 在PND8.8的男性新生儿中,蒂亚加和祖拉诺降低了过活力.
- 这两种治疗都改善了髓基蛋白 (MBP) 染色.
- 提加恢复了女性的寡细胞成熟;这两种治疗都使女性的GABAergic和glutamatergic通路表达正常化.
- 在行为和分子结果中观察到性二态效应.
结论:
- 用 tiagabine 和 zuranolone 进行的神经类固醇替代疗法证明了对早产相关的侮辱的神经保护作用.
- 这些疗法有可能缓解早产婴儿的长期神经发育障碍.
- 性别特定的治疗策略可能会增强治疗效益.
相关概念视频
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...